Paired CRISPR nickase methods build on other technologies in MilliporeSigma's CRISPR patent portfolio, including CRISPR integration. Commercial organizations need MilliporeSigma's IP for CRISPR-based insertion of DNA if they want correct genetic defects in the somatic cells of gene therapy patients. MilliporeSigma is licensing this patent portfolio for all fields of use.